Todas las fotos(1)

Documentos clave

Certificado de origen (COO)/COA

Ver Toda la documentación

Y0000196

Ondansetron for TLC system suitability

Name: Ondansetron for TLC system suitability
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

Ondansetron hydrochloride dihydrate, 1,2,3,9-Tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one hydrochloride, GR 38032F

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización

Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):

C₁₈H₁₉N₃O · HCl · 2H₂O

Número de CAS:

103639-04-9

Peso molecular:

365.85

Número MDL:

MFCD00374371

Código UNSPSC:

41116107

ID de la sustancia en PubChem:

329830878

NACRES:

NA.24

En este momento no podemos mostrarle ni los precios ni la disponibilidad

Productos recomendados

Slide 1 of 10

1 of 10

Y0001346

Ondansetron impurity G

Y0001940

Tigecycline for system suitability

Y0000197

Ondansetron for LC system suitability

Y0001320

Ondansetron impurity F

Y0000218

Ondansetron hydrochloride dihydrate

Supelco

70221

Formato de amonio

Y0001326

Imidazol

Sigma-Aldrich

SMB00937

Fatty Acid Methyl Esters Standard Mixture

Supelco

18919-1AMP

F.A.M.E. mezcla, C4-C24

Sigma-Aldrich

779423

Ammonia solution

grado

pharmaceutical primary standard

familia API

ondansetron

fabricante / nombre comercial

EDQM

aplicaciones

pharmaceutical (small molecule)

Formato

neat

temp. de almacenamiento

2-8°C

cadena SMILES

Cl[H].[H]O[H].[H]O[H].Cc1nccn1CC2CCc3c(C2=O)c4ccccc4n3C

InChI

1S/C18H19N3O.ClH.2H2O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2;;;/h3-6,9-10,13H,7-8,11H2,1-2H3;1H;2*1H2

Clave InChI

VRSLTNZJOUZKLX-UHFFFAOYSA-N

Información sobre el gen

human ... HTR3A(3359)

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Analytical Reference Materials for Pharma QC

Pharmacopeia & Metrological Institute Standards

Reference Materials

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Ondansetron for TLC system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Acciones bioquímicas o fisiológicas

5-HT₃serotonin receptor antagonist

Envase

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Otras notas

Sales restrictions may apply.

Producto relacionado

Referencia del producto

Descripción

Precios

PHR1141

Ondansetron Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

1478618

1478593

1478629

PHR2224

PHR2223

PHR2221

Pictogramas

GHS06,GHS05,GHS09

Palabra de señalización

Danger

Frases de peligro

H301,H318,H410

Consejos de prudencia

P264 - P273 - P280 - P301 + P310 - P305 + P351 + P338 - P391

Clasificaciones de peligro

Acute Tox. 3 Oral - Aquatic Acute 1 - Aquatic Chronic 2 - Eye Dam. 1

Código de clase de almacenamiento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Adherence to national guidelines for antiemesis prophylaxis in patients undergoing chemotherapy for lung cancer: a population-based study.

Daniel R Gomez et al.

Cancer, 119(7), 1428-1436 (2012-12-06)

Nausea and vomiting (N/V) during chemotherapy can have profound clinical and economic consequences. Effective antiemetic agents are available for prophylaxis, but barriers may prevent their use. For this population-based study, the authors assessed the rates of antiemetic prophylaxis use, and

Neuropathic mechanisms in the pathophysiology of burns pruritus: redefining directions for therapy and research.

Ioannis Goutos

Journal of burn care & research : official publication of the American Burn Association, 34(1), 82-93 (2012-11-09)

Pruritus in burn wounds is a common symptom affecting patient rehabilitation. Over the last decades, there has been a resurgence of interest into more effective strategies to combat this distressing problem; nevertheless, no reports exist in the literature to propose

Do children with high body mass indices have a higher incidence of emesis when undergoing ketamine sedation?

Kristi L Kinder et al.

Pediatric emergency care, 28(11), 1203-1205 (2012-11-02)

The objective of this study was to determine if overweight children are more likely than normal-weight children to require ondansetron when undergoing ketamine sedation in a pediatric emergency department. Patients between the ages of 2 and 18 years with an

Clinical and economic impact of oral ondansetron for vomiting in a pediatric emergency department.

Daniel Hervás et al.

Pediatric emergency care, 28(11), 1166-1168 (2012-11-02)

In this study, we determine the clinical impact of 1 dose of oral ondansetron for children with vomiting and evaluate the economic consequences of its use. The strategies compared were administering oral ondansetron in addition to oral rehydration therapy (group

Prophylactic ondansetron does not prevent shivering or decrease shivering severity during cesarean delivery under combined spinal epidural anesthesia: a randomized trial.

Roger M Browning et al.

Regional anesthesia and pain medicine, 38(1), 39-43 (2012-10-30)

Cesarean delivery is commonly performed under regional anesthesia, which is often associated with maternal shivering. This can cause distress and interfere with monitoring. The study objective was to evaluate the antishivering efficacy of ondansetron, which reduces the incidence and severity

Ver todos los artículos relacionados

Questions

Reviews

No rating value

Active Filters

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico